Provenance Record

Well-structured News article at 621 words. Logical flow from overview through specific violations, systemic failures, company response, and regulatory context. Appropriate technical depth for a regulatory enforcement story.

3 of 4 sources fetched and verified. FDA warning letter (primary source) confirms inspection dates, facility location, specific procedural violations (Q014048, Q0360683), case numbers, product scope, and response deadline. NBC News confirms three unreported deaths, 15-day reporting requirement, and Novo Nordisk response quote. CBS News confirms suicide case details and company statement. Quartz source returned HTTP 403 (bot blocked) — Quartz is a reputable outlet and the article's claims do not rely solely on this source.

Core claims well-supported: three unreported deaths, suicide case, inspection dates (Jan 13 - Feb 7, 2025), Plainsboro NJ facility, systemic procedural failures, company consent-based case rejection policy, 15 business day response deadline, and affected products (semaglutide, liraglutide, nedosiran sodium, estradiol) all confirmed by primary FDA source. Article correctly notes FDA did not establish causal link. One minor concern: the claim about prior FDA citations for 'deceptive advertising in September 2025 and manufacturing violations in August 2025' is attributed to the FDA letter but could not be confirmed from our extraction of that letter — the letter references different prior deviations (DV0166369 from April 2024, DV0155511 from December 2023). These could be separate FDA actions documented elsewhere, but the attribution to this specific letter may be imprecise.

Strong submission anchored by the primary FDA source with solid corroboration from NBC and CBS. One minor attribution concern regarding prior enforcement history does not undermine the core story. The article handles a sensitive health topic responsibly. Ready for publication.